Natalizumab doing well outside phase III trials

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1275, 2009-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Natalizumab in MS well tolerated

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Cancer vaccines entering Phase III clinical trials

By Durrant LG Spendlove I

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 489-500

Informa Healthcare

Access to resources Recommend Favorite

Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials

By Stallard Nigel

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 4, 2011-07 ,pp. : 787-801

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pharmacoeconomic evaluations alongside phase III trials?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 424, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Understanding Site Performance Differences in Multinational Phase III Clinical Trials

By Glass Harold E. DiFrancesco Jeffrey J.

International Journal of Pharmaceutical Medicine, Vol. 21, Iss. 4, 2007-01 ,pp. : 279-286

Adis International

Access to resources Recommend Favorite